Revenue Update on Vical Incorporated(NASDAQ:VICL)

Vical Incorporated(NASDAQ:VICL) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 9, 2016. Company reported revenue of $4.12M. Analysts estimated a revenue of $6.95M. Earnings per share were $-0.14. Analysts had estimated an EPS of $-0.40.

In a different note, On Jul 19, 2016, H.C. Wainwright said it Assumes its rating on Vical Incorporated. The shares have been rated ‘Buy’ by the firm.

Vical Incorporated (VICL) shares turned negative on Wednesdays trading session with the shares closing down -0.03 points or -0.69% at a volume of 9,751. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $4.42. The peak price level was also seen at $4.42 while the days lowest was $4.3. Finally the shares closed at $4.32. The 52-week high of the shares is $6.8 while the 52-week low is $2.808. According to the latest information available, the market cap of the company is $40 M.

Several Insider Transactions has been reported to the SEC. On Jul 13, 2016, Lawrence Russell Smith (VP, Vaccine Research) sold 54 shares at $4.46 per share price.Also, On Jun 14, 2016, Robert C Merton (director) purchased 9,000 shares at $4.35 per share price.On Jun 10, 2016, Vijay B Samant (CEO) purchased 15,700 shares at $4.72 per share price, according to the Form-4 filing with the securities and exchange commission.

Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Company has three active independent or partnered development programs in the areas of infectious disease consisted of: Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial using its Vaxfectin formulated therapeutic vaccine for herpes simplex virus type 2 (HSV-2) a cause of recurrent genital herpes and a completed preclinical program with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant to prevent CMV infection before and during pregnancy.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Vical Incorporated - Is it time to Sell?

Top Brokerage Firms are advising their investors on Vical Incorporated. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.